arrow
S

Supranee Buranapraditkun

chulalongkorn university
H指数:25
被引数:2,253

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical phenotypes, endotypes, and biomarker profiles of immediate rituximab hypersensitivity reactions: a prospective pharmacovigilance study

利妥昔单抗即刻超敏反应的临床表型、内型及生物标志物特征:一项前瞻性药物警戒研究

2026-09-030
OA
A 10-year retrospective crosssectional study of severe cutaneous adverse drug reactions in Thailand: Human leukocyte antigen typing and enzyme-linked immunospot assay-assisted drug identification

一项关于泰国严重皮肤不良反应的10年回顾性横断面研究:人类白细胞抗原分型与酶联免疫斑点试验辅助药物识别

2025-11-010
OAAI
Corrigendum to “Cellular immune response to a single dose of live attenuated hepatitis a virus vaccine in obese children and adolescents” [Heliyon Volume 10, Issue 16, August 2024, Article e36610]

勘误:关于“肥胖儿童和青少年对一剂次减毒甲型肝炎病毒疫苗的细胞免疫反应”[Heliyon 第10卷第16期,2024年8月,文章编号:e36610]

Heliyon
IF3.6
2025-08-210
OAAI
Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial

‘Comvigen’二价SARS-CoV-2疫苗的免疫原性和安全性,与Comirnaty二价疫苗在泰国的比较:一项2期非劣效性随机试验

2025-08-150
PREAI
Dynamic changes in immune cell subsets in blood and lymph node over the course of acute HIV infection

急性HIV感染过程中血液和淋巴结中免疫细胞亚群的动态变化

2025-05-260
OA
Activation of CXCR3+ Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development
2025-02-110
OAAI
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
2024-01-292
OAAI
IFN-γ ELISpot-enabled machine learning for culprit drug identification in nonimmediate drug hypersensitivity
2024-01-015
PRE
Initial productive and latent HIV infections originate in vivo by infection of resting T cells
2023-11-152
OAAI